Rituximab-CHOP

DRUG2 trials

Sponsors

Gruppo Italiano Terapie Innovative nei Linfomi, Celgene

Conditions

Diffuse Large B-Cell LymphomaFollicular Lymphoma

Phase 3

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

CompletedNCT00355199

Gruppo Italiano Terapie Innovative nei LinfomiDiffuse Large B-Cell Lymphoma

Start: 2005-05-31End: 2013-03-31Updated: 2017-08-10

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

CompletedNCT01476787

CelgeneFollicular Lymphoma

Start: 2011-12-29End: 2024-04-30Updated: 2025-05-14

Related Papers

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

2026-03-31

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Blood2024-10-078 citations

Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study

Blood2022-11-15

A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma

Haematologica2020-08-1311 citations

Recent Developments in the Treatment of Follicular Lymphoma

Oncology Times2019-05-311 citations

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

New England Journal of Medicine2018-09-05357 citations

Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy

Blood2017-12-073 citations

Study Shows Immunologic Doublet Active Among Relapsed Patients

Oncology Times2017-10-31

TREATMENT WITH COMBINATION OF LENALIDOMIDE AND RITUXIMAB ACHIEVES DURABLE RESPONSES IN A LONG TERM FOLLOW UP OF PATIENTS WITH INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological Oncology2017-06-011 citations

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

2014-10-15191 citations